Autolus Therapeutics presents clinical data updates at EHA Congress

Autolus Therapeutics (AUTL) announces the online publication of three abstracts submitted to the European Hematology Association Congress, to be held June 12-15, 2025, Milan, Italy. Autolus will have two oral and one poster presentation, which includes updated follow up from the FELIX study of obecabtagene autoleucel in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Title: Can CAR T-cell therapy be a definitive treatment for adult r/r B-ALL without transplant? Long-term findings and predictors of sustained remission for obecabtagene autoleucel: Summary: Obe-cel persistence, low disease burden at lymphodepletion and obe-cel use in earlier lines were independent factors associated with better outcomes and longer survival in adult pts with r/r B-ALL. At the current follow-up comprising patients studied for greater than or equal to3 years, 40% of responders are in ongoing remission without subsequent stem cell therapy or other new therapies, suggesting the potential of obe-cel as a definitive treatment for adult r/r B-ALL. An updated analysis with additional follow-up is underway and will be presented. Title: Efficacy and Safety Outcomes of Obecabtagene Autoleucel Stratified by Age in Patients with r/r B-ALL: Summary: Obe-cel treatment was associated with deep and durable remissions resulting in favorable overall remission rate, event free survival, and overall survival with low incidence of Grade greater than or equal to3 CRS and ICANS in both age groups. These findings indicate that obe-cel is effective and has a positive benefit and risk profile regardless of patient age, including in older adults with R/R B-ALL, despite few patients receiving consolidative stem cell therapy. Title: Predicting Hematotoxicity Risk and Outcomes in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia: Should Hematotox Models be CAR Specific rather than Disease Specific: Summary: Although both the CAR-Hematotox model, and the ALL-Hematotox model show potential, ALL-HT appears to improve risk stratification and may be a better predictor of response, survival and safety outcomes in adult patients with r/r B-ALL treated with obe-cel, than CAR-HT. Taken together with other published reports, our data suggest that the strength of HT-model predictions may be CAR specific. Further analyses are needed.